Mallinckrodt Aktie

Mallinckrodt für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN DE: A1W0TN / ISIN: IE00BBGT3753

<
Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
>
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
15.09.2022 04:25:22

FDA Approves Mallinckrodt's Terlivaz For Injection For Treatment Of Hepatorenal Syndrome

(RTTNews) - Mallinckrodt plc (MNKPF) said that the U.S. Food and Drug Administration approved Terlivaz (terlipressin) for injection.

The company noted that the Terlivaz is the first and only FDA-approved product indicated to improve kidney function in adults with hepatorenal syndrome (HRS) with rapid reduction in kidney function, an acute and life-threatening condition requiring hospitalization.

Terlivaz is expected to be available in the U.S. in the coming weeks.

The FDA approval was based on results from the Phase 3 CONFIRM trial, the largest-ever prospective study conducted to assess the safety and efficacy of terlipressin in patients with HRS type 1 (HRS-1) in the U.S. and Canada. The CONFIRM trial met its primary endpoint of Verified HRS Reversal, defined as renal function improvement, avoidance of dialysis and short-term survival.

For More Such Health News, visit rttnews.com

Analysen zu Mallinckrodt PLCmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!